Join us in Philadelphia this September for the DTRF "Together We Will" Weekend: - Register today!

The Desmoid Tumor Research Foundation

April 2016

Proof of principle for bevacizumab activity in desmoid-type fibromatosis.

Author Information

Andreas Beilken,Florian L�nger,H J Raatschen,Viktor Gr�nwald

Clinic for Hematology, Hemostasis, Oncology and Stemcelltransplantation, Medical School Hannover, Carl-Neuberg-Str. 1, Hannover, Germany.,Department of Pathology, Medical School Hannover, Hannover, Germany.,Department of Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany.,Department of Radiology, Medical School Hannover, Hannover, Germany.

Publication

Summary

We treated a patient with progressive DF after failure of chemotherapy for 1 year with singe agent bevacizumab. He achieved a symptomatic and radiologic response while attainning excellent tolerability.

View Abstract